Top Medical News
Systemic antihypertensive medications exert diverse effects on glaucoma, IOP
The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.
Low-concentration atropine eye drops may reduce myopia incidence in high-risk children
Sarah Cheung, 2 days ago

Researchers from the Chinese University of Hong Kong (CUHK) have conducted the world’s first study to show that nightly use of low-concentration (0.05 percent) atropine eye drops may reduce the incidence of myopia in high-risk children.

How does gel stent perform vs trabeculectomy in open-angle glaucoma?
2 days ago
In the treatment of patients with open-angle glaucoma (OAG), gel stent is noninferior to trabeculectomy in terms of reducing intraocular pressure (IOP) by at least 20 percent, according to a study. Trabeculectomy helps reduce IOP to a greater extent, whereas gel stent leads to fewer adverse events (AEs).
Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial
25 Mar 2023
The novel NOV03 ophthalmic drop consisting of perfluorohexyloctane appears to help reduce both signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD), as shown in the results of the phase III MOJAVE study.
Bidirectional genetic link exists between myopia, POAG
24 Mar 2023
Myopia and primary open-angle glaucoma (POAG) share a strong bidirectional, genetic, causal relationship, which is primarily driven by intraocular pressure (IOP), suggest the results of a study.
Higher-dose bevacizumab tied to fewer retreatments in ROP patients
23 Mar 2023
Use of ranibizumab and lower-dose bevacizumab results in a higher rate of retreatment as compared with higher-dose bevacizumab use in patients with retinopathy of prematurity (ROP) initially treated with antivascular endothelial growth factors (anti-VEGFs), a study has shown.
Original New Drug Application Approvals by US FDA (16-28 February 2023)
28 Feb 2023
New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Special Reports
Opacity usually appears later in the development of cataract.
June Chiang, Ph.D, 26 May 2022
A new algorithm objectively determines when intraocular lens implant (IOL) surgery should be performed, regardless of how the opacity looks to the surgeon.
No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia
Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.